EFPIA - NEWSLETTER

EFPIA Newsletter 11 May 2023

Blog

11 May 2023 AMR and its impact on solid organ transplant recipients

AMR is a significant public health concern that can have a significant impact on the health outcomes of solid organ...

The AMR challenge

Jo Atkinson and the threat of AMR

Investing in R&D for new antimicrobials is key to provide patients with better tools to fight resistant bacteria.

Driving R&D to tackle AMR

Dr. Liz Rhee, Vice President and Head, Infectious Disease Clinical Research, MSD discusses the importance of innovation if we are to tackle AMR.

Events

24 MAY 2023

Revealing policy barriers in diabetes care: How we can improve outcomes Online

An event by PwC & EFPIA

Learn more →

30 MAY 2023

Realising the potential of the European Health Data Space for Innovation Residence Palace, Rue de la Loi 155, 1040 Brussels

EFPIA and COPAC are pleased to invite you to an in-person discussion on the key issues that are fundamental in ensuring...

Learn more →

Faster, more equitable access to medicines across Europe

EFPIA’s 2022 Patient WAIT Indicator tracks the availability of new medicines and length of time it takes patients to get them in 37 countries in the EU and EEA. Figures show that, on average, a new medicine will reach patients fastest in Germany in 128 days; this compares with 918 days in Romania and 1351 days in Malta, with a European average of 517 days.

In Europe, the average rate of availability of medicines across all therapy areas has dropped to 47% - down 2% on last year’s figures. Disparities persist between Northern and Western Europe and Southern and Eastern Europe - with an 80% average variance in availability.

Find out more about our commitments to help reduce patient access inequalities.

What we are reading

Impact of Multiple Sclerosis Symptoms (IMSS) survey among People with MS in Europe 11 May 2023 (Survey)

Farmaci, riforma UE. Moll (EFPIA): più equilibrio tra proprietà intellettuale e accesso a cure... 10 May 2023 (Sanita33)

About the EFPIA newsletter

The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.

Tel: +32 (0)2 626 25 55
Communications@efpia.eu

▶